[P4-327]: PATIENT AND CAREGIVER ASSESSMENT OF THE BENEFITS FROM THE CLINICAL USE OF AMYLOID-PET IMAGING

2017 ◽  
Vol 13 (7S_Part_29) ◽  
pp. P1415-P1416
Author(s):  
Rafid Mustafa ◽  
Jared R. Brosch ◽  
Gil D. Rabinovici ◽  
Bradford C. Dickerson ◽  
Maria C. Carrillo ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Amyloid Pet ◽  
Clinical Use ◽  
Amyloid Pet Imaging

scholarly journals Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging

2018 ◽  
Vol 32 (1) ◽  
pp. 35-42 ◽  
Author(s):  
Rafid Mustafa ◽  
Jared R. Brosch ◽  
Gil D. Rabinovici ◽  
Bradford C. Dickerson ◽  
Maria C. Carrillo ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Amyloid Pet ◽  
Clinical Use ◽  
Amyloid Pet Imaging

P2-325: AMYLOID PET IMAGING IN A COMMUNITY NEUROLOGY PRACTICE: FEASIBILITY AND CLINICAL OUTCOMES

2006 ◽  
Vol 14 (7S_Part_15) ◽  
pp. P807-P807
Author(s):  
Michael H. Rosenbloom ◽  
Kathryn A. Wyman-Chick ◽  
Lauren O. Erickson ◽  
Paul Carolan ◽  
Joshua Johnson ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Amyloid Pet Imaging

scholarly journals Amyloid PET imaging: a challenge for research in clinical neuroimaging

2015 ◽  
Vol 3 (1) ◽  
pp. 3-5
Author(s):  
Kirk Frey ◽  
Daniela Perani
Keyword(s):  
Pet Imaging ◽  
Amyloid Pet ◽  
Amyloid Pet Imaging

scholarly journals A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice

2018 ◽  
Vol 46 (3-4) ◽  
pp. 154-167 ◽  
Author(s):  
Yejin Kim ◽  
Paul Rosenberg ◽  
Esther Oh
Keyword(s):  
Positron Emission Tomography ◽  
Clinical Practice ◽  
Pet Imaging ◽  
Clinical Utility ◽  
Patient Management ◽  
Emission Tomography ◽  
Amyloid Pet ◽  
Diagnostic Confidence ◽  
Positron Emission ◽  
Amyloid Pet Imaging

Background: Molecular imaging of brain amyloid for the diagnosis of Alzheimer’s disease (AD) using positron emission tomography (PET) has been approved for use in clinical practice by the Food and Drug Administration (FDA) since 2012. However, the clinical utility and diagnostic impact of amyloid PET imaging remain controversial. We conducted a review of the recent studies investigating clinical utility of amyloid PET imaging with focus on changes in diagnosis, diagnostic confidence, and patient management. Summary: A total of 16 studies were included in the final analysis. Overall rate of changes in diagnosis after amyloid PET ranged from 9 to 68% (pooled estimate of 31%, 95% CI 23–39%). All studies reported overall increase in diagnostic confidence or diagnostic certainty after amyloid PET. Changes in patient management ranged from 37 to 87%; the most common type of change in management reported was either the initiation or discontinuation of planned AD medications. Key Messages: Amyloid PET imaging led to moderate to significant changes in diagnosis, diagnostic confidence, and subsequent patient management. It may be most useful in patients with high level of diagnostic uncertainty even after the completing the standard workup.

P3-370: AN APOEε4 DERIVED STATISTICAL METHOD FOR OPTIMIZING TARGET AND REFERENCE REGIONS FOR AMYLOID-PET IMAGING

2006 ◽  
Vol 14 (7S_Part_23) ◽  
pp. P1231-P1232
Author(s):  
Michael J. Properzi ◽  
Rachel F. Buckley ◽  
Julie C. Price ◽  
Reisa A. Sperling ◽  
Keith A. Johnson ◽  
...  
Keyword(s):  
Statistical Method ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Amyloid Pet Imaging

scholarly journals A new frontier for amyloid PET imaging: multiple sclerosis

2018 ◽  
Vol 46 (2) ◽  
pp. 276-279 ◽  
Author(s):  
Silvia Morbelli ◽  
Matteo Bauckneht ◽  
Selene Capitanio ◽  
Matteo Pardini ◽  
Luca Roccatagliata ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
New Frontier ◽  
Amyloid Pet Imaging
Sign in / Sign up

Export Citation Format

Share Document